On September 4, the ministry of industry and information technology, the ministry of industry and information technology, released its annual list of China's top 100 pharmaceutical industry in 2016. Guo wen, director of the information center of China pharmaceutical industry, mentioned a key word "merger" when analyzing the list of top 100 pharmaceutical industry industries.
Guo wen proposed that the top 100 companies will be the first to advance the merger and acquisition. In 2016, nearly half of the drug industry in the pharmaceutical industry took place in the pharmaceutical industry, involving a total of 60 billion yuan.
▍ m&a achievement top drug firms
More of the top 100 are pharmaceutical companies, active participants in mergers and acquisitions, as well as the biggest beneficiaries. Pharmaceutical companies are the first to join forces, especially in the pharmaceutical industry.
Through the integrated channel and product line diversification, the top 100 promotes its own development.
For example, China resources, through the extension strategy, expands its own circulation channels, achieving the compound growth rate of 14% in 2016.
Mergers and acquisitions, the pace of China resources has not stopped. China resources reorganization north medicine since 2010, gradually increase the intensity of pharmaceutical business integration, establishment of CRC pharmaceutical business group co., LTD., three years to more than 20 group internal business integration and external m&a.
China resources has a surprising number of mergers and acquisitions, as well as the acquisition targets. The first choice of China resources m&a is the top quality circulation leading enterprises, such as jinan citic medicine, suzhou lian, China resources henan, China resources guangdong and so on.
We look at benevolence and the acquisition is swift, buy chain drugstore, become the leading enterprise of pharmaceutical e-commerce.
Meanwhile, the pharmaceutical group is also making acquisitions, which is why, in the past year of 2016, these companies have handed over an impressive presentation.
In October 2016, Shanghai pharma paid 900 million yuan to acquire Vitaco, an Australian health care company, and the future international layout of innovation and generic drugs is expected.
In fact, the company completed 14 acquisitions between 2010 and 2012 alone. In 2013-2015, four more provinces and cities have been added, further strengthening east China, making mergers and acquisitions and setting up 59 enterprises, achieving a record of 9.31 billion yuan.
Guo also suggested that mergers and acquisitions between companies will continue to push the list.
▍ confused many small and medium-sized enterprises in the face of m&a
On one side, the mergers and acquisitions of the top 100 enterprises are in full swing; On one side, many small and medium-sized enterprises are still a little confused about the market environment.
Liu zhenteng, executive chairman of shandong luxin pharmaceutical group co., LTD., said that it is difficult to master the timing of merger and acquisition integration at the site of the medical industry information conference.
In the face of drastic changes in the domestic industry, liu zhenteng believes that companies will suffer from short-term or intermediate pain, but in the long run, they will be able to filter out high-quality enterprises.
There are some policies that allow companies to benefit in the long term, such as consistency reviews, circulation links or production links GMP promotion requirements. There is also a kind of market policy, such as tendering policy and so on, which plays a role in accelerating the integration of enterprises.
Mr Liu argues that there are some concerns about mergers and acquisitions consolidation. One aspect is whether the time point of integration of enterprises is to be able to connect with these policies without the waste of resources.
The culture of many small, consistency evaluation, don't have the ability to put in resources, but big mergers and acquisitions and less able to accord with a country now point to the time of these policies, especially the approval route of transfer, transfer, and so on there is no real open, time is quite difficult to master.
Small and medium-sized pharmaceutical companies are generally in the merger party, is to insist on independence from the big, hard to kill, or join the camp, believe the strong hengqiang. Whatever the alternative, it takes courage to adapt and grow from the perspective of sme.
In the environment of industry shuffling, it is impossible to merge with the small and medium-sized drug companies under the control of the giants, and I am afraid that the fate of the fittest and the fittest will not survive.
Small and medium-sized enterprises have their own troubles in the face of mergers and acquisitions. After the success of drug companies on top of the top 100 list, they are faced with the difficulties of integration.
According to deloitte, nearly half of the companies that have completed overseas mergers and acquisitions have not had the desired effect. The main reason is the lack of integrated experience and corresponding talent. For these follow-up questions, even for the top 100 companies, there is still a long way to go.
|
